TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00759850

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug Eluting Stent (DES)
Description: Open-label randomization was performed after initial angiography by the treating physician when eligibility criteria were met. All patients received in the CCU 70U/Kg i.v. bolus of UFH plus 1000U/h infusion (to maintain an ACT of at least 200 seconds), aspirin intravenously (500 mg) and clopidogrel (300 mg loading dose). All patients received upstream Gp IIb-IIIa inhibitors administration as a routine adjunctive therapy before primary PCI. Postinterventional antiplatelet therapy for all patients included in the three study group, consisted of aspirin (100 mg) indefinitely and clopidogrel (75 mg for six months). Stenting procedures were performed according to standard techniques. The number and length of stents, and the type of BMS to be implanted, were left to the operator's discretion. The operator was allowed to implant DES to cover the entire length of the lesion with coverage of the entire stented segment and of 5 mm proximal and distal segments.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug Eluting Stent (DES)
Description: Open-label randomization was performed after initial angiography by the treating physician when eligibility criteria were met. All patients received in the CCU 70U/Kg i.v. bolus of UFH plus 1000U/h infusion (to maintain an ACT of at least 200 seconds), aspirin intravenously (500 mg) and clopidogrel (300 mg loading dose). All patients received upstream Gp IIb-IIIa inhibitors administration as a routine adjunctive therapy before primary PCI. Postinterventional antiplatelet therapy for all patients included in the three study group, consisted of aspirin (100 mg) indefinitely and clopidogrel (75 mg for six months). Stenting procedures were performed according to standard techniques. The number and length of stents, and the type of BMS to be implanted, were left to the operator's discretion. The operator was allowed to implant DES to cover the entire length of the lesion with coverage of the entire stented segment and of 5 mm proximal and distal segments.
Study: NCT01223924

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M2ES
Description: M2ES IV 7.5mg-90mg
Study: NCT00759850

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug Eluting Stent (DES)
Description: Open-label randomization was performed after initial angiography by the treating physician when eligibility criteria were met. All patients received in the CCU 70U/Kg i.v. bolus of UFH plus 1000U/h infusion (to maintain an ACT of at least 200 seconds), aspirin intravenously (500 mg) and clopidogrel (300 mg loading dose). All patients received upstream Gp IIb-IIIa inhibitors administration as a routine adjunctive therapy before primary PCI. Postinterventional antiplatelet therapy for all patients included in the three study group, consisted of aspirin (100 mg) indefinitely and clopidogrel (75 mg for six months). Stenting procedures were performed according to standard techniques. The number and length of stents, and the type of BMS to be implanted, were left to the operator's discretion. The operator was allowed to implant DES to cover the entire length of the lesion with coverage of the entire stented segment and of 5 mm proximal and distal segments.
Study: NCT02537197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Regular opioid antagonist dosing of disordered gamblers
Study: NCT04461678

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HPV Genotyping Nucleic Acid Assay Kit
Description: The total sample size of screening population is approximately 12,000 cases (all females ≥ 21 years of age). Two cervical cytology samples will be collected from each subject with a tube of SurePath sample followed by a tube of PreservCyt sample. The 1st tube of SurePath liquid-based cytology sample is used for cytology test and BD Onclarity Assay HPV detection. Subjects with cytology test results ≥ ASCUS or positive HPV test results will be suggested to return for baseline colposcopy within approximately 12 weeks.
Study: NCT01485237

Intervention type: OTHER
Intervention: We will compare the resources used by both groups
Description: The main purpose of this study is to review the resource utilization. Secondary objectives include, comparison of resource utilization to other similar disorders (viral pneumonia, bacterial pneumonia, septic shock, ARDS). We will also look at the percentage of patients that required ICU care as compared to those who could be cared for on medical wards. We will determine the resources used by both groups and compare. Finally we will record the frequency of chronic comorbidities in hospitalized adult H1N1 patients.

Intervention type: OTHER
Intervention: We will compare the resources used by both groups
Description: The main purpose of this study is to review the resource utilization. Secondary objectives include, comparison of resource utilization to other similar disorders (viral pneumonia, bacterial pneumonia, septic shock, ARDS). We will also look at the percentage of patients that required ICU care as compared to those who could be cared for on medical wards. We will determine the resources used by both groups and compare. Finally we will record the frequency of chronic comorbidities in hospitalized adult H1N1 patients.
Study: NCT03870698

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic group
Description: The patients in laparoscopic group will underwent pylorus preserving pancreaticoduodenectomy in laparoscopic manners.
Study: NCT01664533

Intervention type: DRUG
Intervention: Erlotinib
Description: Erlotinib was supplied as tablets in the retail product Tarceva.
Study: NCT04828252

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low level laser treatment
Description: The intervention protocol includes 2 wavelength as the experimental group, each of the were 808nm, 660nm, and 1 placebo intervention which output total power is only 0.0072W.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low level laser treatment
Description: The intervention protocol includes 2 wavelength as the experimental group, each of the were 808nm, 660nm, and 1 placebo intervention which output total power is only 0.0072W.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Low level laser treatment
Description: The intervention protocol includes 2 wavelength as the experimental group, each of the were 808nm, 660nm, and 1 placebo intervention which output total power is only 0.0072W.
Study: NCT02119481

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Expressive writing condition
Study: NCT04232384

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Paracentesis
Description: The patients will be asked to lie supine for 10 minutes and no changes in posture will be allowed for this period. Abdominal paracentesis will be done either by blind technique (in case the ascites is clinically detectable) or ultrasonography guided (in cases the ascites is not clinically detectable).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roll Over Paracentesis
Description: Patients with ascites will be rolled over thrice in bed laterally upto 90 degrees on either side (Figure 1) and ascitic fluid sample is drawn within 1 minute of the last rollover. There will be four steps to this i.e roll over to one side at 90 degrees and then 180 degrees to the other side, then back to the first side and then back to the center (to complete three turns). This will be done after the disinfection and cleaning of the anterior abdominal wall have been done and the personnel involved in the procedure are ready for the paracentesis. The ascitic paracentesis will be initiated within one minute of the completion of the turn. One assistant will maintain a stopwatch during this period to ensure compliance with this.
Study: NCT01377376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ 197 and Erlotinib
Description: Oral twice daily administration of ARQ197 and oral once daily administration of erlotinib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and Erlotinib
Description: Oral twice daily administration of placebo and oral once daily administration of erlotinib
Study: NCT04471337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1817080
Description: BAY1817080 will be administered orally as tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1817080
Description: BAY1817080 will be administered orally as tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1817080
Description: BAY1817080 will be administered orally as tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1817080
Description: BAY1817080 will be administered orally as tablet.
Study: NCT03259438

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qigong
Description: Qigong is a form of gentle mind-body movement that originates in China and has traditionally been used for healing purposes. It has been reported to improve energy levels, as well as strength and endurance and mental clarity and equanimity. This study will assess how a 10-week qigong intervention compares to an exercise-nutrition intervention in improving fatigue and vitality in female cancer survivors. On a secondary level, we will asses changes in underlying brain, heart, and peripheral dynamics that occur as a result of the qigong practice to develop a mechanistic understanding of qigong's efficacy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Living (CHIP + Pre-Train)
Description: The Healthy Living active comparator intervention includes two components: plant based nutrition counseling via the Comprehensive Health Improvement Program (CHIP) and core strengthening exercises and light aerobic activity via the Pre-Train exercise program.
Study: NCT02564081

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static Stretching lower limb

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Static stretching Cervical
Study: NCT04473911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLUDARABINE
Description: predetermined dose, intravenously, a predetermined times per cycle Given in both pre stem cell and post stem cell cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLUDARABINE
Description: predetermined dose, intravenously, a predetermined times per cycle Given in both pre stem cell and post stem cell cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYCLOPHOSPHAMIDE
Description: ◦Cyclophosphamide predetermined dose, predetermined number of times in Given in pre-stem cell Regimen #1 Cyclophosphamide predetermined dose, predetermined number of times in cycle, intravenous infusion
Study: NCT03572257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: Patients randomized to the study treatment group will received quetiapine at 0.5 mg/kg, three times a day for 10 days. Doses can be increased up to a maximum of 6 mg/kg/day, in increments of 0.5 mg/kg, based on the subject's clinical delirium symptoms. PRN doses of 0.5 mg/kg can be given up to three times a day based on the clinical judgement of the subject's ICU care team.
Study: NCT04473911

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TBI
Description: Total body irradiation (TBI) once per cycle.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TBI
Description: Total body irradiation (TBI) once per cycle.
Study: NCT04374032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metenkefalin + tridecactide
Description: ENKORTEN® 5 mg + 1 mg Lyophilisate for Solution for Injection
Study: NCT04473911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan, infusion, determined dosage, once per cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus: Predetermined dosage, predetermined number of time in cycle, oral: Please note that doses of sirolimus can be adjusted at the treating physician's discretion given the multiple drugs and other situations which affect its metabolism
Study: NCT03588104

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care as given to diabetes patients by the patient's diabetes care team.
Study: NCT02282488

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low protein formula

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High protein formula
Study: NCT03572257

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomized to the placebo group will be given an equivalent volume of sterile liquid or sugar pill, based on the individual subjects dosing preference or ability. Dosing will be done on the same schedule as the quetiapine group
Study: NCT02530827

Intervention type: DRUG
Intervention: use of lipid-lowering drugs.
Description: The patients shoud be in use of a lipid-lowering drugs previouly, at least one month before of the begining of the study.
Study: NCT04473911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus: Predetermined dosage, predetermined number of time in cycle, oral: Please note that doses of sirolimus can be adjusted at the treating physician's discretion given the multiple drugs and other situations which affect its metabolism

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: ◦Mycophenolate mofetil, oral or iv(predetermined dose or IV TID (based upon actual body weight), at predetermined times per cycle
Study: NCT04374032

Intervention type: DRUG
Group type: OTHER
Intervention: The standard of care
Description: The usual therapeutically established protocol, for the treatment of patients with moderate to severe COVID-19 infection prescribed by The Agency for medicinal products and medical devices of Bosnia and Herzegovina
Study: NCT02052583

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic hypothermia at 32 ° C
Study: NCT04473911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: ◦Mycophenolate mofetil, oral or iv(predetermined dose or IV TID (based upon actual body weight), at predetermined times per cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGI-2001
Description: IV, predetermined dose, weekly to 6 total doses
Study: NCT02052583

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic hypothermia at 34 ° C
Study: NCT00871702

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CD34-TK75 transduced donor lymphocytes
Study: NCT02886338

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: capsule endoscopy
Description: The magnetic navigated CE would enable detailed investigations of the whole upper gastrointestinal tract, including the esophagus, stomach and duodenum. Using this remote magnetic manipulation, capsule endoscope might improve diagnostic accuracy and extend the examination of specific area of interest in the gastrointestinal tract.
Study: NCT03130504

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17α hydroxy progesterone caproate
Description: where patients will have a 17α hydroxy progesterone caproate intramuscular injection every week starting from 24 weeks of gestation till completed 37 weeks
Study: NCT00871702

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Sub Study - 18 FHBG PET/CT Scans
Description: Three 18 FHBG PET/CT Scans will be performed first one at pre-DLI infusion, second 14 days post-DLI infusion and third 30 days post-DLI infusion - patients #3 - #8
Study: NCT04736836

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rifaximin
Description: locally absorbed antibiotic
Study: NCT02456571

Intervention type: DEVICE
Intervention: CTC biomarker expression prevalence

Intervention type: DEVICE
Intervention: CTC biomarker expression prevalence

Intervention type: DEVICE
Intervention: CTC biomarker expression prevalence

Intervention type: DEVICE
Intervention: CTC biomarker expression prevalence
Study: NCT02861118

Intervention type: OTHER
Intervention: No Intervention

Intervention type: OTHER
Intervention: No Intervention
Study: NCT00409396

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Urinary PGEm level
Description: Level of PGEm in urine compared to CRP and fecal calprotectin levels in patients with ulcerative colitis.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fecal calprotectin
Description: Level of fecal calprotectin in comparison to urinary PGEm and serum CRP levels.
Study: NCT02108522

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multivirus Specific T cells
Study: NCT03966092

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadratus lumborum block
Description: * Bilateral Quatratus lumborum block is performed with ultra sound guidance. The high frequency probe is placed right to the umbilicus, and slips laterally to the side to block. It allows showing the three belts of larges muscles of abdomen (External Oblicum, internal oblicum, and transversal of the abdomen). Laterally, these three are merging to from fascia transversalis. Under fascia transversalis, we can see quadratus lumborum muscle. Punction point in lateral, 1cm in the plan separating quadratus lumborum block and fascia transversalis~* 20 ml of ropivacaïne 3.75mg/ml are injected after aspiration test. If in doubt, hydro localisation car be realised.
Study: NCT01160224

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GW766944
Description: Drug: GW766944 (Active Drug Treatment)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is placebo to match.
Study: NCT01699776

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine
Description: 7.5 my b.id. by mouth for 12-14 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin
Description: 1.25 mg once a day by mouth, for 12-14 weeks.
Study: NCT02876484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colesevelam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colesevelam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic Acid

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Study: NCT00937508

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Smoking counseling
Description: Preoperative and postoperative counseling sessions provided by a trained smoking counselor along with placebo.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking counseling
Description: Preoperative and postoperative counseling sessions provided by a trained smoking counselor along with placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline
Description: varenicline (an approved medication for smoking cessation)
Study: NCT04473911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGI-2001
Description: IV, predetermined dose, weekly to 6 total doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYCLOPHOSPHAMIDE
Description: ◦Given in Post Stem Cell cycle of Regimen #1 and #2 Cyclophosphamide predetermined dose, predetermined number of times in cycle, intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYCLOPHOSPHAMIDE
Description: ◦Given in Post Stem Cell cycle of Regimen #1 and #2 Cyclophosphamide predetermined dose, predetermined number of times in cycle, intravenous infusion
Study: NCT02553083

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nexium 40 mg
Description: Nexium 40 mg twice daily for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nexium 40 mg
Description: Nexium 40 mg twice daily for 14 days
Study: NCT04736836

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin
Description: locally absorbed antibiotic
Study: NCT00542555

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: At 13 weeks, the patients receiving placebo were re-randomized to receive either naproxcinod 375 mg bid or naproxcinod 750 mg bid in a 1:1 ratio in the 301E study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxcinod 375 mg
Study: NCT02553083

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amoxicillin 1.5 gr
Description: amoxicillin 1.5 gr twice daily for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline 200 mg
Description: doxycycline 200 mg twice daily for 14 days
Study: NCT00542555

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxcinod 750 mg
Study: NCT02553083

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nexium 20 mg
Description: Nexium 20 mg twice a day for 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clarythromicin 500 mg
Description: clarythromicin 500 mg twice a day for 10 days
Study: NCT00937508

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: sugar pill without any active medication
Study: NCT00739674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan potassium (+ hydrochlorothiazide [HCTZ] + calcium channel blocker [CCB])
Description: Losartan 50 mg or 100 mg once daily for 40 weeks with sequential titration including HCTZ 12.5 mg or 25 mg and CCB only as needed to achieve target blood pressure, as follows:~Patients with mild-moderate hypertension, uncontrolled hypertension on monotherapy, or diabetes:~* Losartan 50 mg~* Losartan 100 mg~* Losartan 100 mg/HCTZ 12.5 mg~* Losartan 100 mg/HCTZ 25 mg~* Losartan 100 mg/HCTZ 25 mg + CCB~Patients with severe hypertension:~* Losartan 50 mg/HCTZ 12.5 mg~* Losartan 100 mg/HCTZ 12.5 mg~* Losartan 100 mg/HCTZ 25 mg~* Losartan 100 mg/HCTZ 25 mg + CCB~* Losartan 100 mg/HCTZ 25 mg + increasing CCB

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: losartan potassium (+ hydrochlorothiazide [HCTZ] + calcium channel blocker [CCB])
Description: Losartan 50 mg or 100 mg once daily for 40 weeks with sequential titration including HCTZ 12.5 mg or 25 mg and CCB only as needed to achieve target blood pressure, as follows:~Patients with mild-moderate hypertension, uncontrolled hypertension on monotherapy, or diabetes:~* Losartan 50 mg~* Losartan 100 mg~* Losartan 100 mg/HCTZ 12.5 mg~* Losartan 100 mg/HCTZ 25 mg~* Losartan 100 mg/HCTZ 25 mg + CCB~Patients with severe hypertension:~* Losartan 50 mg/HCTZ 12.5 mg~* Losartan 100 mg/HCTZ 12.5 mg~* Losartan 100 mg/HCTZ 25 mg~* Losartan 100 mg/HCTZ 25 mg + CCB~* Losartan 100 mg/HCTZ 25 mg + increasing CCB
Study: NCT02553083

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amoxicillin 1gr
Description: amoxicillin 1gr twice a day for 10 days